Literature DB >> 19398952

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

S Boehrer1, L Adès, N Tajeddine, W K Hofmann, S Kriener, G Bug, O G Ottmann, M Ruthardt, L Galluzzi, C Fouassier, M Tailler, K A Olaussen, C Gardin, V Eclache, S de Botton, S Thepot, P Fenaux, G Kroemer.   

Abstract

The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk myelodysplastic syndrome (MDS) to the less favorable forms of high-risk MDS, as well as those enabling transformation to acute myeloid leukemia (AML), are still incompletely understood. Abundant evidence from solid tumors demonstrates that preneoplastic lesions activate signaling pathways of a DNA damage response (DDR), which functions as an 'anticancer barrier' hindering tumorigenesis. Testing the hypothesis that subgroups of MDS and AML differ with respect to DDR, we first assessed markers of DDR (phosphorylation of ATM, Chk-1, Chk-2 and H2AX) in cell lines representing different entities of MDS (P39, MOLM-13) and AML (MV4-11, KG-1) before and after gamma-irradiation. Although gamma-irradiation induced apoptosis and G(2)/M arrest and a concomitant increase in the phosphorylation of ATM, Chk-1 and H2AX in MDS-derived cell lines, this radiation response was attenuated in the AML-derived cell lines. It is noteworthy that KG-1, but not P39 cells exhibit signs of an endogenous activation of the DDR. Similarly, we found that the frequency of P-ATM(+) cells detectable in bone marrow (BM) biopsies increased in samples from patients with AML as compared with high-risk MDS samples and significantly correlated with the percentage of BM blasts. In contrast, the frequency of gamma-H2AX(+) cells was heterogeneous in all subgroups of AML and MDS. Whereas intermediate-1 MDS samples contained as little P-Chk-1 and P-Chk-2 as healthy controls, staining for both checkpoint kinases increased in intermediate-2 and high-risk MDS, yet declined to near-to-background levels in AML samples. Thus the activation of Chk-1 and Chk-2 behaves in accord with the paradigm established for solid tumors, whereas ATM is activated during and beyond transformation. In conclusion, we demonstrate the heterogeneity of the DDR response in MDS and AML and provide evidence for its selective suppression in AML because of the uncoupling between activated ATM and inactive checkpoint kinases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398952     DOI: 10.1038/onc.2009.69

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Cytokinesis failure and attenuation: new findings in Fanconi anemia.

Authors:  Philip J Mason; Monica Bessler
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Authors:  Alena Moudra; Sona Hubackova; Veronika Machalova; Marketa Vancurova; Jiri Bartek; Milan Reinis; Zdenek Hodny; Anna Jonasova
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

4.  EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Authors:  K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont
Journal:  Mol Cancer Res       Date:  2015-05-05       Impact factor: 5.852

5.  Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.

Authors:  Lisa Bodei; Mark Kidd; Giovanni Paganelli; Chiara M Grana; Ignat Drozdov; Marta Cremonesi; Christopher Lepensky; Dik J Kwekkeboom; Richard P Baum; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-02       Impact factor: 9.236

6.  Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Authors:  Silvia Maifrede; Margaret Nieborowska-Skorska; Katherine Sullivan-Reed; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Bac Viet Le; Martyna Solecka; Zhaorui Lian; Elizaveta A Belyaeva; Alina Nersesyan; Marcin M Machnicki; Monika Toma; Nicolas Chatain; Malgorzata Rydzanicz; Huaqing Zhao; Jaroslav Jelinek; Katarzyna Piwocka; Tomasz Sliwinski; Tomasz Stoklosa; Rafal Ploski; Thomas Fischer; Stephen M Sykes; Steffen Koschmieder; Lars Bullinger; Peter Valent; Mariusz A Wasik; Jian Huang; Tomasz Skorski
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

7.  The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion.

Authors:  W Du; S Amarachintha; A Wilson; Q Pang
Journal:  Leukemia       Date:  2016-08-29       Impact factor: 11.528

8.  Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.

Authors:  Roberto R Rosato; Sarah S Kolla; Stefanie K Hock; Jorge A Almenara; Ankita Patel; Sanjay Amin; Peter Atadja; Paul B Fisher; Paul Dent; Steven Grant
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

9.  Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.

Authors:  Ana Paula Zambuzi Cardoso Marsola; Belinda Pinto Simões; Leonardo Carvalho Palma; Maria Gabriela Berzoti-Coelho; Sandra Mara Burin; Fabíola Attié de Castro
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

10.  Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer.

Authors:  Rachel M Guerra; Gregory H Bird; Edward P Harvey; Neekesh V Dharia; Kyle J Korshavn; Michelle S Prew; Kimberly Stegmaier; Loren D Walensky
Journal:  Cell Rep       Date:  2018-09-25       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.